ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, Sun Young*; Oh, Do-Youn; Yanez, Patricio; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernandez, Manuel Gonzalez; Li, Jin; Lowery, Maeve A.; Cil, Timucin; Cruz, Felipe Melo; Qin, Shukui; Luo, Suxia; Pan, Hongming; Wainberg, Zev A.; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Wyrwicz, Lucjan S.哈尔滨医科大学; 浙江大学; 郑州大学; 同济大学
LANCET ONCOLOGY2023-11DOI: 10.1016/S1470-2045(23)00515-6
10被引13阅读
引用收藏
分享

摘要

Background:<bold> </bold>PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy in participants with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma.Methods:<bold> </bold>KEYNOTE-859 is a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial, done at 207 medical centres across 33 countries. Eligible participants were aged 18 years and older with previously untreated histologically or cytologically confirmed locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to receive pembrolizumab or placebo 200 mg, administered intravenously every 3 weeks for up to 35 cycles. All participants received investigator's choice of fluorouracil (intravenous, 800 mg/m(2) per day) administered continuously on days 1-5 of each 3-week cycle plus cisplatin (intravenous, 80 mg/m(2)) administered on day 1 of each 3-week cycle or capecitabine (oral, 1000 mg/m(2)) administered twice daily on days 1-14 of each 3-week cycle plus oxaliplatin (intravenous, 130 mg/m(2)) administered on day 1 of each 3-week cycle. Randomisation was done using a central interactive voice-response system and stratified by geographical region, PD-L1 status, and chemotherapy in permuted block sizes of four. The primary endpoint was overall survival, assessed in the intention-to-treat (ITT) population, and the populations with a PD-L1 combined positive score (CPS) of 1 or higher, and PD-L1 CPS of 10 or higher. Safety was assessed in the as-treated population, which included all randomly assigned participants who received at least one dose of study intervention. Here, we report the results of the interim analysis. This study is registered with ClinicalTrials.gov, NCT03675737, and recruitment is complete.Findings:<bold> </bold>Between Nov 8, 2018, and June 11, 2021, 1579 (66%) of 2409 screened participants were randomly assigned to receive pembrolizumab plus chemotherapy (pembrolizumab group; n=790) or placebo plus chemotherapy (placebo group; n=789). Most participants were male (527 [67%] of 790 participants in the pembrolizumab plus chemotherapy group; 544 [69%] of 789 participants in the placebo plus chemotherapy group) and White (426 [54%]; 435 [55%]). Median follow-up at the data cutoff was 31<middle dot>0 months (IQR 23<middle dot>0-38<middle dot>3). Median overall survival was longer in the pembrolizumab group than in the placebo group in the ITT population (12<middle dot>9 months [95% CI 11<middle dot>9-14<middle dot>0] vs 11<middle dot>5 months [10<middle dot>6-12<middle dot>1]; hazard ratio [HR] 0<middle dot>78 [95% CI 0<middle dot>70-0<middle dot>87]; p<0<middle dot>0001), in participants with a PD-L1 CPS of 1 or higher (13<middle dot>0 months [11<middle dot>6-14<middle dot>2] vs 11<middle dot>4 months [10<middle dot>5-12<middle dot>0]; 0<middle dot>74 [0<middle dot>65-0<middle dot>84]; p<0<middle dot>0001), and in participants with a PD-L1 CPS of 10 or higher (15<middle dot>7 months [13<middle dot>8-19<middle dot>3] vs 11<middle dot>8 months [10<middle dot>3-12<middle dot>7]; 0<middle dot>65 [0<middle dot>53-0<middle dot>79]; p<0<middle dot>0001). @@@ The most common grade 3-5 adverse events of any cause were anaemia (95 [12%] of 785 participants in the pembrolizumab group vs 76 [10%] of 787 participants in the placebo group) and decreased neutrophil count (77 [10%] vs 64 [8%]). Serious treatment-related adverse events occurred in 184 (23%) participants in the pembrolizumab group and 146 (19%) participants in the placebo group. Treatment-related deaths occurred in eight (1%) participants in the pembrolizumab group and 16 (2%) participants in the placebo group. No new safety signals were identified.Interpretation: Participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity compared with participants in the placebo plus chemotherapy group. Therefore, pembrolizumab with chemotherapy might be a first-line treatment option for patients with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma.

学科与关键词

关键词
GASTROESOPHAGEAL JUNCTION
相关
加载中…
  • Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
    Janjigian, Yelena Y.*; Kawazoe, Akihito; Bai, Yuxian; Xu, Jianming; Lonardi, Sara; Metges, Jean Phillipe; Yanez, Patricio; Wyrwicz, Lucjan S.; Shen, Lin; Ostapenko, Yuriy; Bilici, Mehmet; Chung, Hyun Cheol; Shitara, Kohei; Qin, Shu-Kui; Van Cutsem, Eric; Tabernero, Josep; Li, Kan; Shih, Chie-Schin; Bhagia, Pooja; Rha, Sun YoungLancet, 2023, 402(10418): 2197-2208.被引 8
  • Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
    Wyrwicz, L.; Oh, D.; Weber, P.; Bai, Y.; Ryu, M.; Lee, J.; Rivera, F.; Alves, G. Vasconcelos; Garrido, M.; Shiu, K.; Fernandez, M. Gonzalez; Li, J.; Lowery, M.; Cil, T.; Cruz, F.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Rha, S.
  • Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
    Oh, D-Y.; Bai, Y.; Ryu, M. H.; Lee, J.; Li, J.; Luo, S.; Pan, H.; Qu, Y.; Lu, J.; Yang, L.; Yasui, H.; Yabusaki, H.; Yen, C. J.; Chan, W. W. L.; Yamaguchi, K.; Yeh, K-H.; Yin, L.; Bordia, S.; Bhagia, P.; Rha, S. Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
查看全部 →

发表信息

论文状态
公开发表
期刊
LANCET ONCOLOGY
发表日期
2023-11
卷期
第 24 卷, 第 11 期
页码
1181-1195
DOI
10.1016/S1470-2045(23)00515-6
语言
ENGLISH
成果收录
SCIE
资助标注
Merck Sharp and Dohme

作者

  • R

    Rha, Sun Young (通讯) (第一作者)

  • O

    Oh, Do-Youn

查看全部 23 位作者收起作者
  • Y

    Yanez, Patricio

  • B

    Bai, Yuxian

    harbin med univ

  • R

    Ryu, Min-Hee

  • L

    Lee, Jeeyun

  • R

    Rivera, Fernando

  • A

    Alves, Gustavo Vasconcelos

  • G

    Garrido, Marcelo

  • S

    Shiu, Kai-Keen

  • F

    Fernandez, Manuel Gonzalez

  • L

    Li, Jin

    tongji univ

  • L

    Lowery, Maeve A.

  • C

    Cil, Timucin

  • C

    Cruz, Felipe Melo

  • Q

    Qin, Shukui

  • L

    Luo, Suxia

    zhengzhou univ

  • P

    Pan, Hongming

    zhejiang univ

  • W

    Wainberg, Zev A.

  • Y

    Yin, Lina

  • B

    Bordia, Sonal

  • B

    Bhagia, Pooja

  • W

    Wyrwicz, Lucjan S.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417